Literature DB >> 34045449

Chromosomal copy number heterogeneity predicts survival rates across cancers.

Erik van Dijk1, Tom van den Bosch2,3, Kristiaan J Lenos2,3, Khalid El Makrini2,3, Lisanne E Nijman2,3, Hendrik F B van Essen1, Nico Lansu3,4, Michiel Boekhout3,5, Joris H Hageman3,5, Rebecca C Fitzgerald6, Cornelis J A Punt7, Jurriaan B Tuynman8, Hugo J G Snippert3,5, Geert J P L Kops3,4, Jan Paul Medema2,3, Bauke Ylstra1, Louis Vermeulen9,10, Daniël M Miedema11,12.   

Abstract

Survival rates of cancer patients vary widely within and between malignancies. While genetic aberrations are at the root of all cancers, individual genomic features cannot explain these distinct disease outcomes. In contrast, intra-tumour heterogeneity (ITH) has the potential to elucidate pan-cancer survival rates and the biology that drives cancer prognosis. Unfortunately, a comprehensive and effective framework to measure ITH across cancers is missing. Here, we introduce a scalable measure of chromosomal copy number heterogeneity (CNH) that predicts patient survival across cancers. We show that the level of ITH can be derived from a single-sample copy number profile. Using gene-expression data and live cell imaging we demonstrate that ongoing chromosomal instability underlies the observed heterogeneity. Analysing 11,534 primary cancer samples from 37 different malignancies, we find that copy number heterogeneity can be accurately deduced and predicts cancer survival across tissues of origin and stages of disease. Our results provide a unifying molecular explanation for the different survival rates observed between cancer types.

Entities:  

Year:  2021        PMID: 34045449     DOI: 10.1038/s41467-021-23384-6

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  1 in total

Review 1.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

  1 in total
  8 in total

Review 1.  Untangling the web of intratumour heterogeneity.

Authors:  Zheqi Li; Marco Seehawer; Kornelia Polyak
Journal:  Nat Cell Biol       Date:  2022-08-08       Impact factor: 28.213

2.  Extensive protein dosage compensation in aneuploid human cancers.

Authors:  Klaske M Schukken; Jason M Sheltzer
Journal:  Genome Res       Date:  2022-06-14       Impact factor: 9.438

3.  The significance of the fusion partner gene genomic neighborhood analysis in translocation-defined tumors.

Authors:  Elaheh Mosaieby; Petr Martínek; Ondrej Ondič
Journal:  Mol Genet Genomic Med       Date:  2022-05-27       Impact factor: 2.473

4.  Dual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL‑6R/STAT‑3 axis.

Authors:  Anibal Méndez-Clemente; Alejandro Bravo-Cuellar; Salvador González-Ochoa; Maria Santiago-Mercado; Luis Palafox-Mariscal; Luis Jave-Suárez; Fabiola Solorzano-Ibarra; Maria Villaseñor-García; Pablo Ortiz-Lazareno; Georgina Hernández-Flores
Journal:  Oncol Rep       Date:  2022-06-15       Impact factor: 4.136

5.  Molecular characterization of colorectal cancer related peritoneal metastatic disease.

Authors:  Jurriaan B Tuynman; Louis Vermeulen; Kristiaan J Lenos; Sander Bach; Leandro Ferreira Moreno; Sanne Ten Hoorn; Nina R Sluiter; Sanne Bootsma; Felipe A Vieira Braga; Lisanne E Nijman; Tom van den Bosch; Daniel M Miedema; Erik van Dijk; Bauke Ylstra; Ruth Kulicke; Fred P Davis; Nicolas Stransky; Gromoslaw A Smolen; Robert R J Coebergh van den Braak; Jan N M IJzermans; John W M Martens; Sally Hallam; Andrew D Beggs; Geert J P L Kops; Nico Lansu; Vivian P Bastiaenen; Charlotte E L Klaver; Maria C Lecca; Khalid El Makrini; Clara C Elbers; Mark P G Dings; Carel J M van Noesel; Onno Kranenburg; Jan Paul Medema; Jan Koster; Lianne Koens; Cornelis J A Punt; Pieter J Tanis; Ignace H de Hingh; Maarten F Bijlsma
Journal:  Nat Commun       Date:  2022-08-04       Impact factor: 17.694

6.  Prognostic Value of Molecular Intratumor Heterogeneity in Primary Oral Cancer and Its Lymph Node Metastases Assessed by Mass Spectrometry Imaging.

Authors:  Agata Kurczyk; Marta Gawin; Piotr Paul; Ewa Chmielik; Tomasz Rutkowski; Monika Pietrowska; Piotr Widłak
Journal:  Molecules       Date:  2022-08-25       Impact factor: 4.927

7.  Copy-number intratumor heterogeneity as high-risk feature of stage II colon cancer.

Authors:  Tom van den Bosch; Daniël M Miedema; Louis Vermeulen
Journal:  J Pathol       Date:  2022-05-23       Impact factor: 9.883

8.  Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies.

Authors:  Devon A Lukow; Erin L Sausville; Pavit Suri; Narendra Kumar Chunduri; Angela Wieland; Justin Leu; Joan C Smith; Vishruth Girish; Ankith A Kumar; Jude Kendall; Zihua Wang; Zuzana Storchova; Jason M Sheltzer
Journal:  Dev Cell       Date:  2021-08-04       Impact factor: 12.270

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.